Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis

Scandinavian Journal of Rheumatology

Volumn 37, Issue 3, 2008, Pages 200-204

  Park, M C ^a   Park, Y B ^a   Lee, S K ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOGENIC PROTEIN 1; SALAZOSULFAPYRIDINE; BONE MORPHOGENETIC PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SPINE MOBILITY; BLOOD; BONE; CASE CONTROL STUDY; COMPARATIVE STUDY; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); PATHOPHYSIOLOGY; RADIOGRAPHY; WALKING DIFFICULTY;

ADULT; ARTHRITIS, RHEUMATOID; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOBILITY LIMITATION; MOVEMENT; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 45549083413     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701774941     Document Type: Article

References (17)

1. Maksymowych WP. Ankylosing spondylitis: at the interface of bone and cartilage. J Rheumatol 2000;27:2295-301.
2. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
3. Urist MR, Mikulski A, Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci USA 1979;76:1828-32.
4. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Rev 1997;8:11-20.
5. Sampath TK, Maliakal JC, Hauschka PV, Jones WK, Sasak H, Tucker RF, et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 1992;267:20352-62.
6. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, et al. Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. J Clin Invest 1997;100:321-30.
7. Carlsen S, Hansson AS, Olsson H, Heinegard D, Holmdahl R. Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats. Clin Exp Immunol 1998;114:477-84.
8. Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 2005;34:178-90.
9. Braun J, Baraliakos X, Godolias G, Bohm H. Therapy of ankylosing spondylitis - a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005;34:97-108.
10. Garrett S, Jenkinson T,Kennedy LG,Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
11. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis. The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
12. Calin A, Mackay K, Santos H, Brophy S. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999;26:988-92.
13. Fuchs HA. The use of the Disease Activity Score in the analysis of clinical trials in rheumatoid arthritis. J Rheumatol 1993;20:1863-6.
14. Larsen A, Edgren J, Harju E, Laasonen L, Reitamo T. Interobserver variation in the evaluation of radiologic changes of rheumatoid arthritis. Scand J Rheumatol 1979;8:109-12.
15. Flechtenmacher J, Huch K, Thonar EJ, Mollenhauer JA, Davies SR, Schmid TM, et al. Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996;39:1896-904.
16. Huch K, Wilbrink B, Flechtenmacher J, Koepp HE, Aydelotte MB, Sampath TK, et al. Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum 1997;40:2157-61.
17. Lories RJU, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.